Go back to News
NEWS
Íñigo Igartua foresees an increase in demand for Competition teams | El Confidencial
The fight against AI-engineered fraud and anti-competitive behaviour has led to the application of more Competition rules and regulation.
The increase in demand on the Competition teams responds to a clear trend: both the authorities and regulatory production have intensified controls. ‘Instruments have multiplied: merger control, foreign investment control and control of third country subsidies. There are more and more ‘controls’ to be considered in the timing of an operation. In addition, the CNMC is more interventionist than ever: it demanded remedies or opened a second phase in 14% of operations in 2024, and has already opened two second phases in 2025,’ explains Íñigo Igartua.
Press contact
Sandra Cuesta
Director of Business Development, Marketing and Communications
Sandra Cuesta
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
PUBLICATION
17 Jul, 2026
Claim assignment and assignment of right to rescind underlying contract
There is no single answer to the question of whether or not the assignee of a claim has the power to rescind the underlying contract when the assigned debtor defaults. As a general rule, such rescission will not be possible for the assignee.
PUBLICATION
16 Jul, 2026
New EU regulation on the screening of foreign investments
Regulation (EU) 2026/1386 establishes a harmonised and mandatory framework for the screening of foreign investments in the Union and replaces the previous Regulation (EU) 2019/452. Among its most notable new features are the obligation for all Member States to have a national screening mechanism with harmonised minimum requirements; the inclusion within its scope of investments made by European subsidiaries controlled by third-country investors; the implementation of a two-stage national procedure; and the strengthening of the European cooperation mechanism through a risk-screening system and a more stringent “comply or explain” principle.
Finally, the paper analyses the regulation’s impact on Spain, whose current review mechanism must be adapted in areas such as procedural structure, the review of completed transactions, sectoral expansion, and the penalty regime by 17 January 2028.
PUBLICATION
23 Jun, 2026
Pharma & Healthcare No. 49
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
PUBLICATION
09 Jun, 2026
Partial limitation defences that may be raised in relation to the limitation period within a cartel (Supreme Court Judgment no. 681/2026 of 6 May)
A flawed judgment on a problem that has remained unresolved to date in the truck cartel. The issue is not whether the liability-in-solidum regime applies, but whether co-liable parties can raise personal defences.
PUBLICATION
04 Jun, 2026
Unanimous shareholders' agreements and dividends in specie
The Supreme Court and the Madrid Provincial Court, following established legal doctrine, have reiterated that a party to a unanimous shareholders’ agreement acts in bad faith if he or she challenges a company resolution passed in compliance with said shareholders’ agreement. In this case, the shareholders’ agreement provided for the possibility of paying dividends in kind, and the contested resolution — which was passed by a majority at the shareholders’ meeting — transferred certain real estate properties to one of the shareholders (with his consent) in payment of the dividend due to him.
PUBLICATION
27 May, 2026
An action for declaration of invalidity of an already-terminated franchise agreement is admissible
An action for declaration of invalidity of an agreement can almost always be brought, even if the agreement has been performed and terminated.
PUBLICATION
30 Apr, 2026
Pharma & Healthcare No. 48
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
PUBLICATION
26 Feb, 2026
Pharma & Healthcare No. 47
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
PUBLICATION
09 Dec, 2025
Pharma & Healthcare No. 46
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.